Listing ID #2971056
Company Information
Ask for more detail from the seller
Contact SupplierHAVpur - Pharmacology- Provides active immunization against hepatitis A. Indication is Active immunization of patients 12 mo of age and older against disease caused by hepatitis A virus.
VAQTA is indicated for active pre-exposure prophylaxis against disease caused by hepatitis A virus in persons 2 years of age and older. Primary immunization should be given at least 2 weeks prior to expected exposure to HAV. Individuals who are or will be at increased risk of infection by HAV include :
Travelers :
Military Personnel :
Certain Ethnic And Geographic Populations That Experience Cyclic Hepatitis A Epidemics Such As :
Others :
Although the epidemiology of hepatitis A does not permit the identification of other specific populations at high risk of disease, outbreaks of hepatitis A or exposure to hepatitis A virus have been described in a variety of populations in which VAQTA may be useful :
People Exposed To Hepatitis A - For those requiring both immediate and long-term protection, VAQTA may be administered concomitantly with IG. RevaccinationSee,.
Use With Other Vaccines :
VAQTA may be given concomitantly at separate injection sites with typhoid and yellow fever vaccines. The GMTs for hepatitis A when VAQTA, typhoid and yellow fever vaccines were administered concomitantly were reduced when compared to VAQTA alone. Following receipt of the booster dose of VAQTA, the GMTs for hepatitis A in these two groups were observed to be comparable. (See, and,.)
The Advisory Committee on Immunization Practices has stated that limited data from studies conducted among adults indicate that simultaneous administration of hepatitis A vaccine with diphtheria, poliovirus (oral and inactivated), tetanus, oral typhoid, cholera, Japanese encephalitis, rabies, or yellow fever vaccine does not decrease the immune response to either vaccine or increase the frequency of reported adverse events. Studies indicate that hepatitis B vaccine can be administered with VAQTA without affecting immunogenicity or increasing the frequency of adverse events.
Use With Immune Globulin :